Amarin Corporation plc (ADR)  

(Public, NASDAQ:AMRN)   Watch this stock  
Find more results for AMRN
1.62
-0.01 (-0.61%)
Apr 23 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.60 - 1.65
52 week 1.36 - 7.98
Open 1.63
Vol / Avg. 966,705.00/2.30M
Mkt cap 279.35M
P/E     -
Div/yield     -
EPS -1.05
Shares 172.44M
Beta 1.29
Inst. own 32%
Feb 27, 2014
Q4 2013 Amarin Corporation PLC Earnings Conference Call
Feb 27, 2014
Q4 2013 Amarin Corporation PLC Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -152.49% -630.82%
Operating margin -325.43% -691.08%
EBITD margin - -678.95%
Return on average assets -22.63% -59.02%
Return on average equity - -
Employees 185 -
CDP Score - -

Address

2 Pembroke House Upper Pembroke Street 28-32, Dublin 2
DUBLIN,
Ireland
+353-1-6699020 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Amarin Corporation plc (Amarin) is a late-stage biopharmaceutical -company with expertise in lipid science focused on the treatment of cardiovascular disease. The Company�s product candidate is AMR101, an ultra-pure omega-3 fatty acid. It is developing AMR101 for the treatment of patients with high triglyceride levels, or hypertriglyceridemia. In September 2011, it filed a New Drug Application (NDA), with the United States Food and Drug Administration (FDA). In December 2011, it commenced patient dosing in its cardiovascular outcomes study of AMR101, titled REDUCE-IT (Reduction of Cardiovascular Events with eicosapentanoic acid (EPA) - Intervention Trial).

Officers and directors

Lars G. Ekman M.D., Ph.D. Independent Chairman of the Board
Age: 63
Bio & Compensation  - Reuters
John F. Thero CPA President, Chief Executive Officer, Assistant Secretary, Director
Age: 52
Bio & Compensation  - Reuters
Michael Farrell Principal Financial Officer and Principal Accounting Officer
Bio & Compensation  - Reuters
Stephen B. Ketchum Ph.D. President - Research and Development, Senior Vice President
Age: 48
Bio & Compensation  - Reuters
Joseph T. Kennedy JD Senior Vice President, Chief Compliance Officer, General Counsel, Secretary
Age: 45
Bio & Compensation  - Reuters
Aaron D. Berg Senior Vice President - Marketing and Sales
Bio & Compensation  - Reuters
Paul E. Huff Senior Vice President, Chief Commercial Officer
Age: 53
Bio & Compensation  - Reuters
Stuart D. Sedlack Senior Vice President - Corporate Development
Age: 48
Bio & Compensation  - Reuters
Joseph S. Zakrzewski Director
Age: 51
Bio & Compensation  - Reuters
David M. Stack Independent Director
Age: 62
Bio & Compensation  - Reuters